| Literature DB >> 34885530 |
Hung-Yang Lin1, Yi-Jung Lu2, Hsin-Hua Chou3,4, Keng-Liang Ou5,6,7,8,9,10, Bai-Hung Huang5,11, Wen-Chien Lan6, Takashi Saito8, Yung-Chieh Cho5,12, Yu-Hsin Ou13,14, Tzu-Sen Yang15, Pei-Wen Peng16.
Abstract
The present study aimed to synthesize biphasic calcium phosphate ceramics (CaPs) composed of β-tricalcium phosphate (β-TCP) and hydroxyapatite (HAp) from the propagated Scleractinian coral and dicalcium phosphate anhydrous using a solid-state reaction followed by heat treatment at a temperature of 1100 °C for 1 h to 7 days. The as-prepared coral and coral-derived biphasic CaPs samples were characterized through scanning electron microscopy, X-ray diffractometry, Fourier transform infrared spectroscopy, and Raman spectroscopy. The cell response of the biphasic CaPs was evaluated by in vitro cytotoxicity assessment using mouse fibroblast (L929) cells. The bilateral femoral defect rabbit model was used to assess the early local reaction of the coral-derived biphasic CaPs bone graft on tissue. The results confirmed that the co-existence of β-TCP and HAp was formed at 1100 °C for 1 h. The ratio of HA/β-TCP increased as the heat-treatment time increased. The coral-derived biphasic CaPs comprising 61% HAp and 39% β-TCP (defined as HT-3) were not cytotoxic. Furthermore, no significant differences in local tissue reaction were observed between the HT-3 sample and autogenous bone. Therefore, the synthesized coral-derived biphasic CaPs is a candidate for bone grafting due to its good biocompatibility.Entities:
Keywords: bioactive materials; bioceramics; biocompatibility; calcium phosphate; composites
Year: 2021 PMID: 34885530 PMCID: PMC8658566 DOI: 10.3390/ma14237374
Source DB: PubMed Journal: Materials (Basel) ISSN: 1996-1944 Impact factor: 3.623
Figure 1(a) Surgical model and (b) a schematic implantation design in the right distal femur of rabbit.
Figure 2Comparisons between as-prepared coral and commercial coral calcium powder samples. (a) SEM image of the as-prepared coral, (b) a higher magnification SEM image of the as-prepared coral, (c) SEM image of the commercial coral calcium sample, and (d) a higher magnification SEM image of the commercial coral calcium sample.
Figure 3XRD pattern of (a) the as-prepared coral and (b) the commercial coral calcium sample.
Figure 4(a) FTIR and (b) Raman spectra of the as-prepared coral sample.
Figure 5XRD patterns of the samples prepared by the heat treatment of as-prepared coral and DCPA at various durations, including reference spectra for JCPDS 01-084-1988 and 00-009-0169.
Relative phase content (%) in biphasic CaP synthesized for varying durations.
| Phase | HT-0.1 | HT-3 | HT-7 |
|---|---|---|---|
| HAp | 39.8 | 61.0 | 62.6 |
| β-TCP | 60.2 | 39.0 | 37.4 |
Figure 6FTIR spectra of the samples prepared by the heat treatment of various durations of as-prepared coral and DCPA. Green areas indicate the bond regions of groups; gray areas indicate the bond regions of groups; pink areas indicate the bond regions of groups.
Figure 7Raman spectra of the investigated samples prepared by the heat treatment of as-prepared coral and DCPA at different durations.
The results of MTT assay for evaluation of cell viability.
| OD570 nm | Viability (%) | Cell Lysis (%) | |
|---|---|---|---|
| Blank | 0.986 ± 0.002 | 100 | 0 |
| NC | 0.984 ± 0.003 | 100 | 0 |
| PC | 0.098 ± 0.001 | 10 | 90 |
| HT-3 | 0.929 ± 0.035 | 94 | 6 |
| 50% HT-3 | 0.963 ± 0.028 | 98 | 2 |
Figure 8Optical images of the cell morphologies on the investigated samples: (a) blank, (b) negative control, (c) positive control, and (d) HT-3.
Figure 9H & E staining results of the investigated samples after 4 weeks of implantation: (a) control and (b) HT-3.
Histological findings and irritant-ranking scores according to ISO 10993-6: 2016.
| HT-3 ( | Autogenous Bone Group ( | ||
|---|---|---|---|
| Polymorphonuclea | 1.2 ± 1.8 | 0.8 ± 1.1 | 0.68 |
| Lymphocytes | 4.4 ± 0.9 | 3.6 ± 0.9 | 0.20 |
| Plasma cells | 0 | 0 | |
| Macrophages | 0 | 0 | |
| Giant cells | 0 | 0 | |
| Necrosis | 0 | 0 | |
| Neovascularization | 0 | 0 | |
| Fibrosis | 0.6 ± 0.5 | 0.6 ± 0.5 | >0.05 |
| Fatty infiltrate | 2.2 ± 0.5 | 2.4 ± 0.9 | 0.67 |